Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARATIVE EFFECTS OF MONOTHERAPY WITH MAGNESIUM AND COMBINED THERAPY WITH MAGNESIUM AND Β-BLOCKER ON PRIMARY MITRAL VALVE PROLAPSE WITH HEART RHYTHM DISORDERS

https://doi.org/10.20996/1819-6446-2007-3-3-22-26

Full Text:

Abstract

Aim. To compare effects of monotherapy with magnesium and combined therapy with magnesium and β-blocker on primary mitral valve prolapse (MVP) with heart rhythm disorders.

Material and methods. 71 patients with primary MVP 1-2 degree and heart rhythm disorders were involved in the study. The patients were split into three groups. Group I (25 persons) received monotherapy with magnesium orotate at a dose of 1-3 g per day; group II (28 persons) received combined therapy with magnesium orotate and betaxolol. The control group (18 persons) received no therapy. Initially and after 12 weeks of observation all the patients underwent electrocardiography (ECG), ECG-Holter monitoring, echocardiography and autonomic balance assessment by A.M. Vein’s questionnaire.

Results. In 12 weeks of treatment groups I and II showed positive dynamics in the MVP manifestations, including significant reduction in severity of the autonomic dysfunction syndrome, ECG positive dynamics, antiarrhythmic effect, decrease in the degree of prolapse, diminution of mitral regurgitation and left auricle volumes. More substantial hemodynamic effects were found in the group of patients who received combination therapy.

Conclusion. Combined therapy has proven advantages in comparison with magnesium monotherapy in terms of daily quantity of extrasystoles, reduction in heart rate, decrease in autonomic disfunction and normalization of intracardiac hemodynamics.

About the Authors

E. G. Nurtdinova
Bashkir State Medical University, Ufa
Russian Federation


A. N. Zakirova
Bashkir State Medical University, Ufa
Russian Federation


T. B. Khairetdinova
Bashkir State Medical University, Ufa
Russian Federation


References

1. Вейн А.М. Вегетативные расстройства: Клиника, диагностика, лечение. М.: Медицинское информационное агентство; 2003.

2. Домницкая Т.М., Дьяченко А.В., Куприянова О.О., Домницкий М.В. Клиническое значение применения магния оротата у подростков с синдромом дисплазии соединительной ткани сердца. Кардиология 2005;45(3):76-81.

3. Клеменов А.В. Первичный пролапс митрального клапана. Современный взгляд на проблему. Н.-Новгород: Издательство НГМА; 2002.

4. Кушаковский М.С. Аритмии сердца. Руководство для врачей. 3-е изд. С-Пб: Фолиант; 2004.

5. Мухарлямов Н.М., Норузбаева А.М., Бочкова Д.Н. Пролабирование митрального клапана (клинические варианты). Тер арх 1981;53(1):72-7.

6. Степура О.Б., Мельник О.О., Шехтер А.Б. и др. Результаты применения магниевой соли оротовой кислоты «Магнерот» при лечении больных с идиопатическим пролапсом митрального клапана. Российские медицинские вести 1999;4(2):64-9.

7. Шиллер Н.Б., Осипов М.А. Клиническая эхокардиография. М.: Практика; 2005.

8. Barlow J.B. Mitral valve billowing and prolaps-an overview. Aust. N Z J Med 1992;22: Suppl 5:541-9.

9. Boudoulas H., Wooley C.F. Mitral valve prolapse syndrome. Evidence of hyperadrenergic state. Postgrad Med 1988;Spec No:152-62.

10. Coghlan H.C., Natello G. Erythrocyte magnesium in symptomatic patients with primary mitral valve prolapse: relationship to symptoms, mitral leaflet thickness, joint hypermobility and autonomic regulation. Magnes Trace Flem 1991-1992;10(2-4):205-14.

11. Davies A.O., Mares A., Pool J.L., Taylor A.A. Mitral valve prolapse with syndroms of beta-adrenergic hypersensitivity. Beta 2-adrenergic receptor supercoupling with desensitization on isoproterenol exposure. Am J Med 1987;82:193-201.

12. Durlach J. Primary mitral valve prolapse: a clinical form of primary magnesium deficit. Magnes Res 1994;7:339-40.

13. Levy D., Savage D. Prevalence and clinical features of mitral valve prolapse. Am Heart J 1987;113:1281-90.

14. Savage D.D., Garrison R.J., Devereux R.D. et al. Mitral valve prolapse in the general population. I. Epidemiologic features: the Framingham Study. Am Heart J 1983;106:571-6.

15. Sniezek-Maciejewska M., Dubiel J.P., Piwowarska W. et al. Ventricular arrhythmias and the autonomic tone in patients with mitral valve prolapse. Clin Cardiol 1992;15:720-4.

16. Takamoto T., Nitta M., Tsujibayashi T. et al. The prevalence and clinical features of pathologically abnormal mitral valve leaflets (myxomatous mitral valve) in the mitral valve prolapse syndrome: an echocardiographic and pathological comparative study [in Japanese]. J Cardiol Suppl 1991;25:75-86.

17. Zeana C.D. Recent data of mitral valve prolaps and magnesium deficit. Magnes Res 1988;1:203-11.


For citation:


Nurtdinova E.G., Zakirova A.N., Khairetdinova T.B. COMPARATIVE EFFECTS OF MONOTHERAPY WITH MAGNESIUM AND COMBINED THERAPY WITH MAGNESIUM AND Β-BLOCKER ON PRIMARY MITRAL VALVE PRO￾LAPSE WITH HEART RHYTHM DISORDERS. Rational Pharmacotherapy in Cardiology. 2007;3(3):22-26. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-3-22-26

Views: 291


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)